Interestingly, such statements have not deterred its use, and chromium supplementation by the general public and in subjects with diabetes in particular has surpassed our ability as a scientific community to provide evidence regarding its safety and efficacy. However, routine use of chromium in subjects with diabetes is not currently recommended, and the most recent 2006 Clinical Practice Recommendations from the American Diabetes Association stated that “the existence of a relationship between chromium picolinate and either insulin resistance or type 2 diabetes was highly uncertain” ( 5). One supplement that has attracted considerable clinical interest is chromium ( 4). Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. −0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo.ĬONCLUSIONS-This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. RESULTS-Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo ( n = 12) or the sulfonylurea plus 1,000 μg Cr as CrPic ( n = 17) for 6 months. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. RESEARCH DESIGN AND METHODS-Thirty-seven subjects with type 2 diabetes were evaluated. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. OBJECTIVE-Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |